Issue 46 - The Cancer Letter

Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.

SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.

LOGIN SUBSCRIBE NOW

SEARCH DATE

SEARCH TEXT

Cancel

OK

Cancel

OK

Delete Account

Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below

How Medical Devices Do Harm

Two Docs Who Broke the Code

The Root Causes of Harm From Medical Devices

Vodra: 510(k) Does Not Assess Risk; Needs to be Split Into Multiple Risk Groups

Pilot: Don't Change 510(k), Put More Money Into Enforcing FDA Reporting Laws

Daniel: FDA Does Not Have A Reliable Surveillance System For Medical Devices

Congress Passes $1.1 Trillion Omnibus Bill, Funding Government Through Sept. 2016, Boosting NIH Budget by $2 Billion

The Year in Review

In Brief

Raymond DuBois Named Dean of MUSC College Of Medicine

John “Drew” Ridge elected medical staff president at Fox Chase – Temple Health

Bhramar Mukherjee appointed associate director for population science at University of Michigan Comprehensive Cancer Center

Joseph Smith Jr. awarded Huggins Medal from the Society of Urologic Oncology

Society of Toxicology honors award recipients, including Richard Adamson with the Founders Award

Albert Einstein Cancer Center awarded NIH grant

OHSU and Cancer Research UK to collaborate on early detection

St. Jude opens proton therapy center

IU Simon Cancer Center taking high school and college applicants for its Summer Research Program

HealthWell Foundation launches fund for underinsured multiple myeloma patients

Drugs & Targets

FDA Approves Bendeka Injection

Stem Cell Theranostics and CapellaBio launch collaboration on cardiotoxicity

Amgen enters into agreement with GSK to reclaim rights to Prolia, XGEVA, and Vectibix

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login